Matthew Sung

Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy

SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads

Targeted glycan degradation potentiates the anticancer immune response in vivo

Aberrant intracellular metabolism of T‐ DM 1 confers T‐ DM 1 resistance in human epidermal growth factor receptor 2‐positive gastric cancer cells

A view on drug resistance in cancer

CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity

Current and future perspectives of liquid biopsies in genomics-driven oncology

Liquid biopsies come of age: towards implementation of circulating tumour DNA

Strategies and challenges for the next generation of antibody–drug conjugates

Development of therapeutic antibodies for the treatment of diseases

Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression

The “Utility” of Highly Toxic Marine-Sourced Compounds

Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019

Surface-Enhanced Raman Spectroscopy for Bioanalysis: Reliability and Challenges

SERS‐Fluorescence Joint Spectral Encoded Magnetic Nanoprobes for Multiplex Cancer Cell Separation

Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)

Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer

Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device

Mechanisms of Resistance to Antibody–Drug Conjugates

Abstract 2113: Caveolae-mediated endocytosis as a novel mechanism of resistance to T-DM1 ADC

Abstract 818: NG-HER2 ADC (PF-06804103) is superior to trastuzumab emtansine in a mouse 'avatar' head-to-head clinical trial